Susquehanna International Group’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,642
Closed -$8.3K 13279
2025
Q4
$8.3K Buy
1,642
+137
+9% +$1.49K ﹤0.01% 12072
2025
Q3
$15.5K Sell
1,505
-2,664
-64% -$24.8K ﹤0.01% 12075
2025
Q2
$35K Sell
4,169
-2,942
-41% -$27.5K ﹤0.01% 12208
2025
Q1
$66K Sell
7,111
-1,527
-18% -$29.2K ﹤0.01% 11764
2024
Q4
$194K Buy
8,638
+2,386
+38% +$75.4K ﹤0.01% 10757
2024
Q3
$234K Sell
6,252
-467
-7% -$17.9K ﹤0.01% 10141
2024
Q2
$252K Buy
6,719
+3,564
+113% +$130K ﹤0.01% 9839
2024
Q1
$106K Sell
3,155
-435
-12% -$15.8K ﹤0.01% 11182
2023
Q4
$143K Buy
3,590
+880
+32% +$31K ﹤0.01% 11015
2023
Q3
$86.2K Buy
2,710
+1,498
+124% +$56.6K ﹤0.01% 11033
2023
Q2
$40.4K Buy
1,212
+117
+11% +$4.48K ﹤0.01% 11416
2023
Q1
$48.6K Sell
1,095
-3,176
-74% -$255K ﹤0.01% 11708
2022
Q4
$323K Sell
4,271
-1,047
-20% -$98K ﹤0.01% 8909
2022
Q3
$512K Buy
5,318
+3,813
+253% +$533K ﹤0.01% 8423
2022
Q2
$253K Sell
1,505
-1,928
-56% -$293K ﹤0.01% 10021
2022
Q1
$637K Sell
3,433
-9,353
-73% -$1.94M ﹤0.01% 8298
2021
Q4
$3.42M Sell
12,786
-1,347
-10% -$353K ﹤0.01% 4419
2021
Q3
$4.13M Buy
14,133
+7,719
+120% +$2.25M ﹤0.01% 4288
2021
Q2
$1.59M Sell
6,414
-651
-9% -$167K ﹤0.01% 6492
2021
Q1
$2.02M Buy
7,065
+6,633
+1,535% +$2.65M ﹤0.01% 5889
2020
Q4
$121K Sell
432
-8,960
-95% -$3.32M ﹤0.01% 10388
2020
Q3
$3.83M Buy
9,392
+4,547
+94% +$2.34M ﹤0.01% 3454
2020
Q2
$2.81M Buy
4,845
+3,136
+183% +$1.43M ﹤0.01% 3900
2020
Q1
$391K Buy
+1,709
New +$296K ﹤0.01% 7457

Other funds holding CODX

Susquehanna International Group's CODX Position: Q1 2026 in Review

Susquehanna International Group sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 1,642 shares — an estimated $8.3K sold.

Susquehanna International Group first reported a position in CODX in Q1 2020 and held it in 24 quarters. The position peaked at $4.13M in Q3 2021. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • Susquehanna International Group reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 1,642 Co-Diagnostics shares in Q1 2026, an estimated $8.3K.
  • Susquehanna International Group first reported a position in Co-Diagnostics in Q1 2020 and held it in 24 quarters.
  • Susquehanna International Group's Co-Diagnostics position peaked at $4.13M in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.